anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To obtain a disinfectant widely effective for gram-positive bacteria such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus and a gram-negative bacteria such as Klebsiella pneumoniae and Pseudomonas aeruginosa and the other microorganisms including fungi.  <P>SOLUTION: This disinfectant comprises an antibacterial coloring agent, an antibacterial medicine and an organic acid. The disinfectant comprises, particularly preferably, gentiana violet, a citric acid-based buffering agent and polymixin. The disinfectant exhibits synergistic effect on the gram-negative bacteria, particularly by combination of three agents. The disinfectant is a pharmaceutical preparation which enables not only enhancement of sterilization effect and enlargement of antibacterial spectrum, but also pH adjustment by buffer action and can contribute to alleviation of pain due to by irritating property of pH and attenuation of corrosive action by pH.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE:To obtain a skin-whitening cosmetic having excellent skin whitening effect and sufficient storage stability and high safety. CONSTITUTION:The skin-whitening cosmetic is obtained by blending at least one extract of galenical drug selected from the group consisting of Pinellie Tuber, Trichosanthis Fructus, Trichosanthis Radix and Dioscoreae radix. Concretely, about 100g of dried material of Pinellie Tuber which is a galenical drug is pulverized by a mixer and pulverized material thereof and 500ml 50% ethyl alcohol are put in flask and the pulverized material is subjected to reflux extraction at 50 deg.C for 1hr while stirring. After extraction, this solution is filtered with suction and the resultant filtrate is concentrated under reduced pressure at 50 deg.C using an evaporator. Then the resultant concentrate is dried under reduced pressure to provide 3.6g brawn crystal. 14.5g, 6.2 g and 3.2g extracts are obtained from about 100g dried material of Trichosanthis Fructus, trichosanthis Radix and Dioscoreae radix which are galenical drugs as similarly as mentioned above, respectively. The resultant extract is blended as an active ingredient in amount of 0.01-5.0% based on the cosmetic.
Lavender oil in 15 ml opaque dark colored bottles closed with metal caps to prevent volatility to the venture group and 40 2×2 cotton pads were delivered. Patients were asked to apply lavender oil 30 minutes before going to bed. Deep breathing increases the concentration of aromatic substances in the body. The time it takes for essential oils to be absorbed into the blood circulatory system is about 30 minutes for complete absorption by the body. Information was given about dripping 3 drops of lavender oil on cotton pads and placing them 15-20 cm away from the pillow. Patients were told that they should apply lavender oil for 30 days and re-prepare the lavender oil dripped onto a new pad each night, and that the bedroom should be ventilated and free of different odors. A message was sent to the patients to remind them of the application on their phones for 30 days.
In approximately 50 randomly selected patients (group 1), from the second day of admission until the end of hospitalization, a 15-minute manual stimulation of the submandibular and sublingual bib was performed internally and externally. In addition, oral hygiene was performed in patients, taking into account the tongue and cheeks.
SURVANTA is administered directly to the target organ, the lungs, where biophysical effects occur at the alveolar surface. In surfactant-deficient premature rabbits and lambs, alveolar clearance of radio-labelled lipid components of SURVANTA is rapid. Most of the dose becomes lung-associated within hours of administration, and the lipids enter endogenous surfactant pathways of reutilization and recycling. In surfactant-sufficient adult animals, SURVANTA clearance is more rapid than in premature and young animals. There is less reutilization and recycling of surfactant in adult animals. 

Limited animal experiments have not found effects of SURVANTA on endogenous surfactant metabolism. Precursor incorporation and subsequent secretion of saturated phosphatidylcholine in premature sheep are not changed by SURVANTA treatments. 

No information is available about the metabolic fate of the surfactant-associated proteins in SURVANTA. The metabolic disposition in humans has not been studied.
OBJECTIVE: To determine the prevalence of sexual dysfunction in women with COPD and the factors related to its presence.
METHODS: Cross-sectional observational study during 2021, including women with COPD diagnosed by spirometry through convenience sampling. Data on age, smoking status, spirometric data, comorbidities and medications used were collected. A sexual health questionnaire was administered.
RESULTS: The study included 101 women with a mean age of 59.7 (11.3) years. All had experienced a change in sexual activity, with 44% attributing it to COPD. Among them, 51.5% experienced dyspnea during coitus. The prevalence of sexual dysfunction was 52.5%. Women with sexual dysfunction were older and had a lower Tiffeneau index. Furthermore, they consumed alcohol more frequently and had hypertension and cerebrovascular disease, and less often, they had diabetes and heart failure. However, they scored lower on the Charlson index corrected for age. Patients with sexual dysfunction used inhaled triple therapy less frequently.
CONCLUSIONS: Sexual dysfunction is common in women with COPD. Further studies are needed to investigate its causes, mechanisms, and potential treatments.
There is evidence in the literature that youth with intellectual/developmental disabilities (IDD) experience mental health issues to a greater extent compared to youth without IDD. In addition, transition from pediatric to adult services may be a period of increased anxiety and mental health problems for these youth. This study used a retrospective cohort design using population level administrative health data to compare mental health diagnoses between youth with IDD and youth without IDD; particularly examining the period when youth transition from pediatric health services to adult health services. In addition, this study compared the mental health of youth with various types of IDD (Down syndrome, autism, fetal alcohol syndrome and other rarer diagnoses). Results showed that at the population level youth with IDD have greater odds of anxiety/depression or psychotic illness than youth without IDD. Adjusted odds of anxiety/depression or psychotic illness also varied with age, income level, sex, and type of IDD. Youth with fetal alcohol syndrome had the greatest odds of both anxiety/depression and a psychotic illness. Odds of anxiety/depression increased from age 15-19 years old. Odds of a psychotic illness increased from age 15 to age 24 years old.
Patients randomized to continuous EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last a minimum of 30 and a maximum of 48 hours. During this time, one interruption to a maximum of two hours for diagnostic purposes will be allowed. Reactivity testing using auditory and nociceptive stimuli will be performed at least twice during the recording time. Recordings will be visually interpreted by certified electroencephalographers (i.e., interpretation of the automated algorithm only won't be allowed) using the 2013 American Clinical neurophysiology nomenclature; interpretations will be communicated within two hours of their completion to the treating team.
Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
Faced with the increasing prevalence of chronic kidney disease (CKD), portable monitoring of CKD-related biomarkers such as potassium ion (K+), creatinine (Cre), and lactic acid (Lac) levels in sweat has shown tremendous potential for early diagnosis. However, a rapidly manufacturable portable device integrating multiple CKD-related biomarker sensors for ease of sweat testing use has yet to be reported. Here, a portable electrochemical sensor integrated with multifunctional laser-induced graphene (LIG) circuits and laser-printed nanomaterials based working electrodes fabricated by fully automatic laser manufacturing is proposed for non-invasive human kidney function monitoring. The sensor comprises a two-electrode LIG circuit for K+ sensing, a three-electrode LIG circuit with a Kelvin compensating connection for Cre and Lac sensing, and a printed circuit board based portable electrochemical workstation. The working electrodes containing Cu and Cu2O nanoparticles fabricated by two-step laser printing show good sensitivity and selectivity toward Cre and Lac sensing. The sensor circuits are fabricated by generating a hydrophilic-hydrophobic interface on a patterned LIG through laser. This sensor recruited rapid laser manufacturing and integrated with multifunctional LIG circuits and laser-printed nanomaterials based working electrodes, which is a potential kidney function monitoring solution for healthy people and kidney disease patients.
[Problem] To provide a dispersion that blends inorganic oxide particles at high concentrations and has excellent storage stability. [Solution] A dispersion having inorganic oxide particles dispersed in an oil-based medium and containing a C18 or higher ester oil and a polyhydroxystearic acid. The inorganic oxide particles are at least one type selected from the group consisting of zinc oxide, iron oxide, cerium oxide, zirconium oxide, and bismuth oxide. The polyhydroxystearic acid content is 0.5-8.0 wt% of the total dispersion weight. The amount of blended silicone-based component is no more than 10.0 wt% of the total dispersion weight. The inorganic oxide particles constitute at least 51.0 wt% of the total dispersion.
The anterior vaginal wall is incised in the midline from the level of the bladder neck up to vaginal apex or anterior vaginal fornix. The bladder is sharply dissected from the vaginal wall with pubocervical fascia attached to the bladder wall. The fascia is approximated in the midline with several simple interrupted 0 polyglactin 910 sutures or equivalent. The surplus of distended vaginal epithelium is trimmed. The vaginal incision is closed using a continuous non-locking polyglactin 910 2-0 suture or equivalent. Indometacin rectal suppository 100 mg is inserted transrectally for early postoperative pain management.
The present invention, the method for preparation of salt aerosol with predefined s concentration belongs to the field of medical techniques. It can be used for treating respiratory tract problems and for preventive purposes, both in salt chambers of in-patient and out-patient clinics. The aim of the present invention is to develop method for preparation of salt aerosol with predefined concentration and size of salt particles activated with kinetic energy, by which dry coarse salt is directed by help of determined dosage process onto intensively operating salt-grinding instrument. The crystal structure of coarse salt breaks due to impacts with grinding instrument; the salt particles activate with kinetic energy and the aerosol with required quality is prepared in the grinding chamber by mixing of salt particles with compressed air with controlled flow. By help of such method a homogeneous salt aerosol can be prepared with predetermined concentration and salt particles activated with kinetic energy. The produced salt aerosol is directed smoothly by help of additional compressed air into the salt chamber, where the salt therapy (halotherapy) process with improved quality is carried out.
Antigens found in cells transformed by the hepatitis B virus, other than the structural antigens of hepatitis B virus, and designated as antigen HBs, antigen HBc, antigen HBe and polymerase-DNA are new. These antigens are characterised in that serum obtd. from subjects suffering from prim. liver cancer contains antibodies which act specifically against the antigens. The antigen may be isolated from (1) daughter cells of human or animal prim. liver cancer; (2) cells transformed by hepatitis B virus and (3) animal or human metastases, autopsy or hepatic biopsy remains. Antibodies specifically active against the antigens may be obtd. from (1) serum of patients suffering from prim. liver cancer; (2) serum of animals immunised with the antigens; (3) monoclonal prods. obtd. by cellular fusion of human or animal immunocytes, immunised with the antigen and the tumoural immunocytes or (4) monoclonal prods. obtd. by viral transformation of antibody producing cells. The antigens and their antibodies are used in therapapy and diagnosis of chronic hepatic infections (prim. liver cancer). The antigens or antibodies may be coupled to enzymes, radioactive isotopes or inert particles for use in diagnosis or therapy e.g. coupling with an alkaline phosphatase or with technetium 99M (Tc 99M).
Increasing evidence suggests that autophagy plays a major role during renal fibrosis. Transcription factor EB (TFEB) is a critical regulator of autophagy- and lysosome-related gene transcription. However, the pathophysiological roles of TFEB in renal fibrosis and fine-tuned mechanisms by which TFEB regulates fibrosis remain largely unknown. Here, we found that TFEB was downregulated in unilateral ureteral obstruction (UUO)-induced human and mouse fibrotic kidneys, and kidney-specific TFEB overexpression using recombinant AAV serotype 9 (rAAV9)-TFEB in UUO mice alleviated renal fibrosis pathogenesis. Mechanically, we found that TFEB's prevention of extracellular matrix (ECM) deposition depended on autophagic flux integrity and its subsequent blockade of G2/M arrest in tubular cells, rather than the autophagosome synthesis. In addition, we together RNA-seq with CUT&Tag analysis to determine the TFEB targeted gene ATP6V0C, and revealed that TFEB was directly bound to the ATP6V0C promoter only at specific site to promote its expression through CUT&Run-qPCR and luciferase reporter assay. Interestingly, TFEB induced autophagic flux integrity, mainly dependent on scaffold protein ATP6V0C-mediated autophagosome-lysosome fusion by bridging with STX17 and VAMP8 (major SNARE complex) by co-immunoprecipitation analysis, rather than its mediated lysosomal acidification and degradation function. Moreover, we further investigated the underlying mechanism behind the low expression of TEFB in UUO-induced renal fibrosis, and clearly revealed that TFEB suppression in fibrotic kidney was due to DNMT3a-associated TFEB promoter hypermethylation by utilizing methylation specific PCR (MSP) and bisulfite-sequencing PCR (BSP), which could be effectively recovered by 5-Aza-2'-deoxycytidine (5A-za) to alleviate renal fibrosis pathogenesis. These findings reveal for the first time that impaired TFEB-mediated autophagosome-lysosome fusion disorder, tubular cell G2/M arrest and renal fibrosis appear to be sequentially linked in UUO-induced renal fibrosis and suggest that DNMT3a/TFEB/ATP6V0C may serve as potential therapeutic targets to prevent renal fibrosis.
PCT No. PCT/US96/18321 Sec. 371 Date Apr. 22, 1998 Sec. 102(e) Date Apr. 22, 1998 PCT Filed Nov. 12, 1996 PCT Pub. No. WO97/17967 PCT Pub. Date May 22, 1997This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These componds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
A monitor camera (18) is arranged for monitoring an ID unit (42 of a medical staff. The ID of a staff who is opening a storage cabinet (12) is identified and authenticated by a management device (22). When the authentication is successful, a shelf (28) of the storage cabinet (12) is unlocked. An RFID reader (34) is arranged on the storage cabinet (12) so as to read an RF ID of an article in the shelf (28) when the shelf (28) is opened and closed and identify an article placed or removed according to the difference between the ID lists when the shelf is opened and closed. When a medical staff takes a medical product or medical instrument out of the storage cabinet, it is possible to automatically record who took out which medical product. Moreover, it is possible to prevent taking out of a medical product by an unauthorized person.
The present invention discloses a preparation method of compound stemona sessilifolia cough-relieving granule. The preparation method comprises the steps of: (1) weighing medicinal raw materials; (2) extracting the medicinal materials, wherein in the extract drying method an oven is used for drying under reduced pressure or microwave is used for drying; and (3) preparing. According to the invention, the product is extracted and dried, and is granulated in the form of dry extract powder. The prepared granule is completely in conformity with the rules of quality indicators in appearance and color, solubility, granularity and other indicators. Each batch is uniform in quality. The method makes the medicine extract be medicine completely according to the standard. The contents of effective pharmacological ingredients are ensured. The quality and efficacy of the finished granules are ensured.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to neurosurgery, neurology, and can be used in treating complicated spinal trauma accompanied by hypoxia and body tissue ischemia. That is ensured by perineural radicular paravertebral block. The block contains the introduction of a mixture containing 15 ml of 1% novocaine, 15 ml of Mexidol, containing 750 mg of Mexidol and 10 ml of 0.5 % novocaine. ^ EFFECT: method allows to activate energy synthesising mitochondrial functions and to improve energy metabolism in a cell due to optimal concentration of an antioxidant drug mixed with an anaesthetic. ^ 1 ex
* The dosage of buprenorphine and naloxone sublingual tablets should be progressively adjusted in increments/decrements of 2 mg/0.5 mg or 4 mg/1 mg buprenorphine/naloxone to a level that holds the patient in treatment and suppresses opioid withdrawal signs and symptoms.
  * The maintenance dose of buprenorphine and naloxone sublingual tablets are generally in the range of 4 mg/1 mg buprenorphine/naloxone to 24 mg/6 mg buprenorphine/naloxone per day depending on the individual patient. The recommended target dosage of buprenorphine and naloxone sublingual tablet is 16 mg/4 mg buprenorphine/naloxone/day as a single daily dose. Dosages higher than 24 mg/6 mg have not been demonstrated to provide any clinical advantage.
  * When determining the prescription quantity for unsupervised administration, consider the patient’s level of stability, the security of his or her home situation, and other factors likely to affect the ability to manage supplies of take-home medication.
  * There is no maximum recommended duration of maintenance treatment. Patients may require treatment indefinitely and should continue for as long as patients are benefiting and the use of buprenorphine and naloxone sublingual tablets contributes to the intended treatment goals.
Williams syndrome (WS) is a multisystem developmental disorder caused by deletion of 26-28 genes, including the elastin gene, located on chromosome 7q11.23. Cardiovascular disease in WS, including obstructive vascular disease and hypertension, and relatively mild skin changes are caused by the elastin gene deletion. Even though all WS subjects are missing one copy of this gene, the expression of cardiovascular problems is highly variable, ranging from no significant disease to severe generalized arteriopathy leading to infant death. The causes of vascular variability are currently unknown, and male gender is the only disease modifier described to date. Clinically, skin is described as abnormally soft, smooth and easily mobilized , while ultrastructurally the elastic fibers are abnormal with reduced amorphous elastin.

The overall objective of this study is to establish quantitative norms that can be used to determine the severity of vascular disease in elastin insufficiency and then to identify risk factors that contribute to that variability. It is also important to determine how stable/variable these findings are over time.
PURPOSE:To obtain a monoclonal antibody by immunizing an animal with an AMP deaminase purified from sheep brain, fusing the obtained spleen cell of the animal to a myeloma cell and culturing the obtained hybridoma. CONSTITUTION:AMP deaminase separated from sheep brain is purified by various column chromatography processes until the enzyme becomes a simple substance judged by electrophoresis. The purified deaminase is used as an immunogen and an animal is immunized with the enzyme. The spleen cell of the animal is collected and fused with a myeloma cell to obtain a hydridoma. The hybridoma is cultured and the objective monoclonal antibody is separated from the supernatant liquid of the cultured product or the hybridoma is transplanted into an animal body and the monoclonal antibody is separated from the ascites. The obtained monoclonal antibody can be used for the quick detection and determination of AMP deaminase in body fluid, etc.
Systems and methods for model-driven system integration on a ventilator comprise a modeled exhalation flow. Ventilator flow sensors contain components that are easily damaged or impacted and have high rates of failure. Knowledge failure frequency and type may help determine when to replace, clean, or calibrate a flow sensor. A modeled exhalation flow may be trained for a ventilator. Additionally, the modeled exhalation flow may be compared to a flow sensor flow to determine a specific failure. Additionally or alternatively, the modeled exhalation flow may supplement, weight, or replace a faulty flow sensor measurement. These systems and methods may assist in identifying an inaccurate flow sensor measurement and/or providing a more accurate modeled flow estimate, thus increasing accuracy in patient-ventilator interactions.